MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.

PLAINSBORO, N.J., Sept. 3, 2024. The Lancet has published a new pooled, participant-level analysis of patients with heart failure with mildly reduced...

Semaglutide's cardiovascular benefits remain effective in individuals with impaired kidney function, offering heart protection even with reduced...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as...

Finerenone is effective in decreasing the incidence of heart failure and cardiovascular mortality. This finding has been reported based on a...

Finerenone is effective in decreasing the incidence of heart failure and cardiovascular mortality. This finding has been reported based on a...

A Perth professor who has significantly changed the treatment of cancer patients worldwide will trial his method on patients who are suffering from...

A Perth professor who has significantly changed the treatment of cancer patients worldwide will trial his method on patients who are suffering from...

MONDAY, Sept. 9, 2024 -- Empagliflozin confers kidney-protective benefits for patients with acute myocardial infarction (MI) and an increased risk...